RT Journal Article
T1 Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism
A1 Arenas Bermejo, Carolina
A1 Pérez Alenza, María De Los Dolores
A1 García San José, Paula
A1 Llauet, Lidia
A1 Pérez-López, Laura
A1 Melián, Carlos
A1 Feldman, Edward C.
AB Background: Results of ACTH stimulation test (ACTHst), pre- and post-trilostane serum cortisol concentrations (SCCs), urine concentration (urine-specific gravity [USG]), and urine cortisol : creatinine ratios (UCCRs) are common variables used to monitor trilostane treatment of dogs with pituitary-dependent hyperadrenocorticism (PDH). However, none has consistently discriminated dogs receiving an adequate dose (A) from those overdosed (O) or underdosed (U).Objectives: To assess and compare recommended monitoring variables, including serial SCCs in a cohort of dogs with PDH treated with trilostane.Animals: Privately owned dogs with PDH (n = 22) and 3 healthy dogs (controls).Methods: Prospective, multicenter, 2-day study. On day “a” (randomized): ACTHst was completed. Day “b” (>2 to <7 days later): SCCs were assessed -0.5 hours, immediately before, and 1, 2, 2.5, 3, 3.5, 4, 6, 8, and 12 hours after trilostane administration. On the first study day, urine collected at home was assessed for USG, UCCR and owner opinions regarding PDH were categorized as: A (clinical signs resolved), U (remains symptomatic), or ill (possible O).Results: At 27 pairs of evaluations, 7 dogs were categorized as A, 19 U, and 1 possible O (excluded from the study). There was overlap in SCC results from the A and U dogs at every time point. Results of USG, UCCR, and ACTHst did not discriminate A from U dogs. Trilostane suppresses SCC within 1 hour of administration and its duration of action in most PDH dogs is <8 hours.Conclusions and Clinical Importance: No single variable or group of variables reliably discriminated A dogs from U dogs during trilostane treatment for PDH.
PB Wiley
YR 2020
FD 2020-07-02
LK https://hdl.handle.net/20.500.14352/107256
UL https://hdl.handle.net/20.500.14352/107256
LA eng
NO Arenas Bermejo, Carolina, et al. «Laboratory Assessment of Trilostane Treatment in Dogs with Pituitary‐dependent Hyperadrenocorticism». Journal of Veterinary Internal Medicine, vol. 34, n.o 4, julio de 2020, pp. 1413-22. DOI.org (Crossref), https://doi.org/10.1111/jvim.15830.
DS Docta Complutense
RD 6 abr 2025